The domestic patent for ‘POLIGO’, the original technology, has already been registered in March 2019, and the patent for expanding the original technology registered this time is an effective skin penetration delivery system that can securing the exclusive right of POLIGO technology for the development of skin disease treatments It is a type of technology.
The patent added this time not only enables basic treatment by inhibiting the mRNA of the target gene that causes the disease, but also overcomes the disadvantages of nucleic acid therapeutics which are difficult to pass through the skin barrier (stratum corneum), and transforms various PNA. It is an advanced platform technology that can effectively pass through the stratum corneum of the skin from the epidermis to the dermis by controlling the size of nanoparticles through
An official from Seasun Therapeutics said, “The stratum corneum of the skin plays a role in protecting against stress or external stimulation, so drugs cannot pass through the skin layer easily, so the development of drugs that penetrate the skin without a delivery vehicle separately is essential for the development of treatments for skin diseases.” “Starting from this patent registration, we intend to seriously secure rights in major foreign countries, and we intend to accelerate the development of antisense oligonucleotide (ASO) treatments for PNA-based skin disease. it can be applied to skin diseases based on accumulated data and registered patents,” he said.
Meanwhile, with the US patent registration of POLIGO, the source technology, in 2020, SEASUN Therapeutics completed the process of patent registration of eye disease, psoriasis and atopic dermatitis treatment using POLIGO technology in the same year.
Based on this, it has now started to develop a wet macular degeneration treatment in the form of eye drops and has successfully completed the efficacy evaluation in primates, and the development of psoriasis and atopic dermatitis treatments has also completed internal validation and is preparing to enter . the pre-clinical phase.
In addition, we are developing treatments for various diseases such as dry macular degeneration, pancreatic cancer, glioblastoma, Alzheimer’s disease, and NASH Reporter Jang Jong-ho bellho@sportschosun.com
